Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Sponsors » Advances in Clinical Genomics Profiling » FDA Approves Novartis' Capmatinib, Foundation Medicine CDx for Metastatic NSCLC

FDA Approves Novartis' Capmatinib, Foundation Medicine CDx for Metastatic NSCLC

May 06, 2020
|
staff reporter

NEW YORK – The US Food and Drug Administration on Wednesday approved capmatinib (Novartis' Tabrecta) for treatment of patients with metastatic non-small cell lung cancer.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Working Out the Effect

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Increased Genetic Privacy in Florida

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

Attention-Grabbing in Two Ways

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

Nature Papers Describe CRISPR Plant Editing Methods, DNA-PAINT Improvements, More

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.

What's Popular?

In Regulatory News & FDA Approvals

  1. Centogene Gets Emergency Use Authorization for PCR-Based Coronavirus Test

  2. FDA Grants EUAs for PCR Coronavirus Tests, Nasal Swab Self-Collection Kit

  3. FDA Grants Emergency Use Authorization for LifeHope Labs Coronavirus Test

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.